SCHEDULE 13D/A: RA Capital Management Divests Significant Stake in ITEOS THERAPEUTICS, Reducing Ownership Below 5%

RA Capital Management, L.P. and its affiliates have significantly reduced their beneficial ownership in ITEOS THERAPEUTICS, INC. through a series of warrant exercises and open market sales, bringing their stake below the 5% threshold.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") filed Amendment No. 3 to their Schedule 13D for ITEOS THERAPEUTICS, INC.
• The amendment details a reduction in the Reporting Persons' aggregate beneficial ownership of ITEOS THERAPEUTICS, INC. common stock to 2,134,806 shares, representing 4.9% of the class.
• On May 13, 2025, RA Capital Healthcare Fund, L.P. net exercised 3,026,000 pre-funded warrants, receiving 3,025,614 shares of common stock.
• On May 16, 2025, RA Capital Healthcare Fund, L.P. net exercised an additional 2,031,285 pre-funded warrants, receiving 2,031,030 shares of common stock.
• Following these exercises, the Reporting Persons conducted open market sales:
• On May 15, 2025, RA Capital Healthcare Fund, L.P. sold 3,017,776 shares at a weighted average price of $8.00 per share, and RA Capital Nexus Fund, L.P. sold 378,645 shares at $8.00 per share.
• On May 19, 2025, RA Capital Healthcare Fund, L.P. sold 255,929 shares at a weighted average price of $8.37 per share, and RA Capital Nexus Fund, L.P. sold 32,116 shares at $8.37 per share.
• As a result of these transactions, the Reporting Persons ceased to be beneficial owners of more than five percent of ITEOS THERAPEUTICS, INC. securities on May 19, 2025.

Sentiment

Score: 3

Explanation: The significant reduction in beneficial ownership by a major institutional investor like RA Capital Management, L.P. is generally perceived as a negative signal for the company's stock, suggesting a potential lack of conviction or strategic divestment.

Negatives

• A major institutional investor, RA Capital Management, L.P., has significantly reduced its stake in ITEOS THERAPEUTICS, INC., falling below the 5% beneficial ownership threshold.
• The divestment of a substantial portion of shares by a prominent healthcare-focused fund may signal a loss of confidence or a strategic exit, potentially leading to negative market sentiment.

Risks

• The reduction in beneficial ownership by a significant institutional investor like RA Capital Management, L.P. could lead to negative market perception and potential downward pressure on ITEOS THERAPEUTICS, INC.'s stock price.
• The divestment might be interpreted by other investors as a lack of conviction in the company's future prospects or valuation.

Future Outlook

The Reporting Persons have ceased to be beneficial owners of more than five percent of ITEOS THERAPEUTICS, INC. securities, indicating that they no longer intend to maintain a significant reportable stake above this threshold.

Industry Context

In the biotechnology and pharmaceutical industry, a significant reduction in stake by a major healthcare-focused investment fund like RA Capital Management can be interpreted negatively by the market. Such a move might signal concerns about the company's clinical pipeline, regulatory progress, competitive landscape, or overall valuation, potentially impacting investor confidence and stock performance.

Stakeholder Impact

• Shareholders: The divestment by a major institutional investor could lead to decreased investor confidence and potential downward pressure on the stock price.
• Potential Investors: May view the reduction in stake as a cautionary signal, influencing their investment decisions.

Next Steps

• The Reporting Persons will no longer be required to file Schedule 13D amendments unless their beneficial ownership again exceeds the 5% threshold.

Key Dates

Recommendation

Keywords

ITEOS THERAPEUTICS INC., RA Capital Management, Schedule 13D, SEC filing, Beneficial Ownership, Stock Sales, Warrant Exercise, Institutional Investor, Biotechnology, Healthcare Fund